Overview

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Active Biotech AB
Treatments:
Dexamethasone
Ixazomib
Lenalidomide